Cite

    Gourzoulidis, G. et al. (2022). Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. Expert review of pharmacoeconomics & outcomes research. pp. 259-269. [Online].